941 studies (2 from unattributed sources) on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 26 | 99.51% | View COA → |
| Qingdao Sigma Chemical | 23 | 99.51% | View COA → |
| Peptide Sciences | 21 | 99.71% | View COA → |
| Nexaph | 18 | 98.41% | View COA → |
| Simple Peptide | 16 | 99.86% | View COA → |
| Peptide Crafters | 16 | 99.8% | View COA → |
| (unknown) | 16 | 99.57% | View COA → |
| Aminos Research | 15 | 99.73% | View COA → |
Recent certificates: #63635 (99.885%) · #62991 (99.9%) · #42777 (99.91%) · #22090 (99.8%) · #22091 (99.7%) · #14540 (99.9%)
Manufacturers with published third-party certificates of analysis for Semaglutide. Open a vendor to see every batch we've verified.
**Optimizing the injection experience for semaglutide users is critical for long-term adherence and patient satisfaction.** If one pen device or formulation significantly reduces injection site pain, it could directly…
If this trial demonstrates positive results, it could **fundamentally alter the management of diabetic kidney disease in Type 1 Diabetes**. Currently, GLP-1RAs are not standard therapy for kidney protection in T1D, un…
The development of an oral formulation for **semaglutide** represents a significant advancement, potentially transforming **diabetes** and **obesity** management by improving patient convenience and adherence. **Under…
This study introduces a groundbreaking strategy for **next-generation metabolic therapeutics** by demonstrating that peptide-directed nuclear receptor targeting can achieve superior efficacy while mitigating systemic …
This study provides compelling evidence that **semaglutide's neuroprotective effects in an AD model persist for an extended period (60 days) even after treatment cessation**, suggesting a disease-modifying potential b…
**Reframing DPN as a redox-driven neurovascular-immune disorder shifts focus from symptomatic relief to targeting underlying pathology.** This new framework emphasizes the **blood-nerve barrier (BNB)** as a crucial th…
Semaglutide treatment in metabolically challenged 5xFAD mice reduced body weight, improved glucose tolerance, normalized cholesterol, and enhanced spatial memory, alongside decreased Aβ levels.
This systematic review reinforces the growing evidence that **GLP-1 receptor agonists** represent a promising therapeutic avenue for **MASLD** and **MASH**, especially for individuals with co-existing **obesity** or *…
This real-world data reinforces semaglutide's broad utility beyond just glycemic control, demonstrating significant benefits for **body composition** and **cardiometabolic risk reduction** in a diverse obese populatio…
This study provides compelling pharmacovigilance evidence suggesting several widely used antidiabetic drugs, including GLP-1 agonists like **dulaglutide** and **liraglutide**, SGLT2 inhibitors like **empagliflozin**, …
This systematic review suggests **GLP-1RAs may offer a novel adjunctive strategy for individuals struggling with alcohol use disorder**, particularly those with co-occurring metabolic conditions. While the reductions …
This real-world data suggests that **oral semaglutide could be a valuable adjunct therapy for HFpEF patients with T2DM**, offering benefits beyond glycemic control. For peptide users and clinicians, this implies a pot…
**Oral semaglutide offers a promising, multi-faceted therapeutic option for patients grappling with the triple burden of HFrEF, T2D, and obesity.** This real-world evidence reinforces its efficacy beyond just glycemic…
This research provides a critical step towards diversifying the toolkit for oral peptide delivery, potentially reducing reliance on SNAC and its associated formulation challenges. **The findings suggest that MCFA-base…
**Patients on GLP-1RAs undergoing operative ankle fracture fixation may face an elevated risk of hardware failure and impaired bone healing.** This finding suggests the need for careful preoperative risk assessment an…
This review suggests a potential signal for increased **retinal vascular events** with **semaglutide** use, particularly retinal arterial occlusions. **Clinicians and patients should be aware of this potential, especi…
This novel `TTP-S` framework offers a powerful tool for neuroscientists, potentially revolutionizing how brain activity is mapped in response to complex stimuli and states. **Researchers can now identify activated bra…
This novel oral **SD@SEDDS** formulation for semaglutide represents a significant step towards overcoming the current limitations of oral peptide delivery, potentially enhancing **patient compliance** and expanding ac…
This case serves as a crucial reminder for clinicians to **maintain vigilance for thyroid nodules in patients undergoing GLP-1 RA therapy**, even though current evidence does not establish a causal link to **papillary…
This case series offers compelling, albeit preliminary, evidence that a personalized approach combining a **ketogenic diet with low-dose semaglutide** could be a superior strategy for weight loss, specifically by pres…
A new clinical trial will assess individualized anti-obesity medication (AOM) strategies, including **Semaglutide**, in patients with **bipolar disorder** to optimize weight loss.
Semaglutide's impact on Apnea-Hypopnea Index (AHI) and metabolic parameters was evaluated in a 15-patient real-world study of T2DM/obesity with OSA.
This meta-analysis provides robust, quantitative evidence supporting **semaglutide as a valuable therapeutic option for obesity-related HFpEF**. Given semaglutide's existing approval for obesity, these findings could …
These findings significantly expand the potential application of **semaglutide** beyond its established use in diabetes, offering a new therapeutic avenue for **non-diabetic patients with obesity and CKD**, including …
A comprehensive review details how semaglutide improves glycemic control, weight, and cardiovascular health by modulating inflammatory, lipid, and extracellular matrix pathways.
This analysis provides a critical framework for clinicians and policymakers to prioritize cardiovascular prevention strategies based on both clinical efficacy and economic sustainability. **Integrating cost-effectiven…
While no results are yet available, this type of real-world evidence study is vital for understanding how **oral semaglutide** performs outside of controlled clinical trials. **Real-world data can highlight adherence …
If successful, this trial could introduce a **novel combination therapy for obesity and overweight**, potentially offering enhanced weight loss compared to semaglutide alone. For individuals seeking advanced weight ma…
**Comparing two established GLP-1R agonists** like semaglutide and exenatide ER is crucial for optimizing **Type 2 Diabetes** management. The results of this trial, once published, will offer direct head-to-head data,…
This study carries substantial implications for the future landscape of **Type 2 Diabetes** management, particularly for patients seeking highly effective, non-injectable therapeutic options. Should higher doses of **…
This research provides critical insights for clinicians and patients regarding the practical management of **oral semaglutide** therapy. **Understanding the differential impact of missed doses on oral semaglutide's PK…
**GLP-1 RAs provide clinically meaningful cardiorenal protection in CKD patients, offering benefits that are additive to those of SGLT2 inhibitors.** This reinforces their crucial role in managing high-risk individual…
This comprehensive pooled analysis provides strong reassurance regarding the hepatic safety of **Orforglipron**, an oral `GLP-1 RA`, for long-term use in individuals with **obesity** or **T2D**. Given the high prevale…
**Semaglutide offers marked and consistent cardiovascular risk reduction across a broad spectrum of patients and doses**, reinforcing its role beyond glycemic control and weight management. This finding suggests that …
This research provides initial insights into the epigenetic mechanisms underlying **Semaglutide's** effects in **MOSH**, suggesting its benefits extend beyond weight loss to direct cellular programming. **Understandin…
This updated data provides compelling evidence for **semaglutide** as an effective intervention for **severe and complicated pediatric obesity**, a population with limited treatment options. The observed significant r…
This real-world data provides strong evidence that **semaglutide offers superior weight loss and glycemic control compared to dulaglutide** in patients with **type 2 diabetes**, particularly within an urban, predomina…
**Semaglutide offers significant primary cardiovascular protection** for a particularly high-risk population: obese individuals with **Type 2 Diabetes Mellitus** and **Rheumatoid Arthritis**. This real-world evidence …
This review provides a critical roadmap for developing the first clinically validated neuroprotective treatments for **glaucoma**, moving beyond sole reliance on IOP reduction. **It highlights specific agents like nic…
The CKD-bioMatch study will evaluate a biomarker-targeted treatment approach against standard of care to reduce **eGFR** decline in **CKD** patients with albuminuria.
This planned trial is highly relevant for **optimizing semaglutide treatment protocols** and improving patient experience. If a 16-week flexible titration significantly reduces GI-AEs, it could lead to updated clinica…
If successful, this trial could fundamentally shift the management of **diabetic cardiac autonomic neuropathy (DCAN)**, offering a targeted therapeutic strategy beyond general glycemic control. **For peptide users and…
**Establishing bioequivalence** for different semaglutide formulations and delivery devices is crucial for expanding access and flexibility in **obesity** management. If successful, this study could pave the way for n…
This analysis highlights **Survodutide's** potential to offer comprehensive metabolic improvements beyond simple weight reduction, a significant advantage for individuals with **Type 2 Diabetes** and **obesity**. The …
Identifying **LY6D** and its associated `GRB2-AMPK-SREBP1c` axis provides a **novel therapeutic target** for **MASLD** beyond existing GLP-1 and FXR-agonist approaches. This discovery could lead to new drug developmen…
This study introduces a powerful, rapid, and non-destructive analytical tool that could significantly enhance the monitoring of therapeutic peptide stability. **For peptide manufacturers and formulators, this method o…
This pilot provides crucial **practical guidance for clinicians and diabetes educators** considering `GLP-1R` agonist therapy for **CFRD**. It suggests that **semaglutide** can be a valuable adjunct to insulin, partic…
This review fundamentally shifts the perspective on <b>semaglutide's</b> role in cognitive health, suggesting its primary utility may be in <b>preventing neurodegeneration by addressing metabolic and inflammatory risk…
Childhood-onset **craniopharyngioma** treatment frequently causes severe hypothalamic obesity, leading to metabolic, cognitive, and psychosocial impairments, significantly reducing quality of life and increasing morta…
A Phase III randomized non-inferiority trial compared semaglutide formulations for chronic weight management in Indian adults with obesity, assessing comparative efficacy and safety.
Free, no account — handy when you're working with Semaglutide.